IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$698.47+8.23 (+1.19%)
Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –
IDEXX Laboratories total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
IDEXX Laboratories's total debt was $449.86M at Jun 30, 2026. For fiscal 2025 it was $449.84M, down 27.2% from the year before. The highest annual figure on record is $908.48M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $449.84M | -27.2% |
| FY2024 | Dec 31, 2024 | $617.57M | -11.5% |
| FY2023 | Dec 31, 2023 | $697.88M | -9.3% |
| FY2022 | Dec 31, 2022 | $769.37M | -9.5% |
| FY2021 | Dec 31, 2021 | $850.20M | -6.4% |
| FY2020 | Dec 31, 2020 | $908.48M | +30.0% |
| FY2019 | Dec 31, 2019 | $698.91M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $449.86M | -14.3% |
| Q1 FY2026 | Mar 31, 2026 | $449.85M | -27.5% |
| Q4 FY2025 | Dec 31, 2025 | $449.84M | -27.2% |
| Q3 FY2025 | Sep 30, 2025 | $524.82M | -15.9% |
| Q2 FY2025 | Jun 30, 2025 | $524.81M | -24.5% |
| Q1 FY2025 | Mar 31, 2025 | $620.73M | -10.8% |
| Q4 FY2024 | Dec 31, 2024 | $617.57M | -11.5% |
| Q3 FY2024 | Sep 30, 2024 | $623.90M | -18.8% |
| Q2 FY2024 | Jun 30, 2024 | $694.86M | -10.0% |
| Q1 FY2024 | Mar 31, 2024 | $695.78M | -9.8% |
| Q4 FY2023 | Dec 31, 2023 | $697.88M | -9.3% |
| Q3 FY2023 | Sep 30, 2023 | $768.80M | +1.1% |
| Q2 FY2023 | Jun 30, 2023 | $771.84M | +0.5% |
| Q1 FY2023 | Mar 31, 2023 | $771.35M | -0.3% |
| Q4 FY2022 | Dec 31, 2022 | $769.37M | -9.5% |
| Q3 FY2022 | Sep 30, 2022 | $760.81M | -10.8% |
| Q2 FY2022 | Jun 30, 2022 | $768.00M | -15.1% |
| Q1 FY2022 | Mar 31, 2022 | $773.38M | -14.4% |
| Q4 FY2021 | Dec 31, 2021 | $850.20M | -6.4% |
| Q3 FY2021 | Sep 30, 2021 | $853.02M | -5.6% |
| Q2 FY2021 | Jun 30, 2021 | $905.06M | +29.5% |
| Q1 FY2021 | Mar 31, 2021 | $903.72M | – |
| Q4 FY2020 | Dec 31, 2020 | $908.48M | – |
| Q3 FY2020 | Sep 30, 2020 | $903.30M | – |
| Q4 FY2019 | Dec 31, 2019 | $698.91M | – |
See a number that looks wrong?